Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Nonylphenol polyoxyethylene ethers, often summarized as NP-9, found their origins in the surge of surfactant research around the middle of the twentieth century. Chemistry and industry grew side by side, each feeding the other’s appetite for cleaner, more efficient ways to separate substances or reduce surface tension. Nonylphenol, a product of phenol and nonene, paired with ethylene oxide chemistry to give rise to these versatile surfactants. In pharmaceutical development, NP-9 captured industry attention by offering solubility enhancements not common to earlier emulsifiers. Continuous evolution in pharmacopeia standards—BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia)—challenged chemists to continually adjust purity and labeling, reflecting a global awareness of safety and quality. Decades in, NP-9’s complex path remains a mirror of chemical innovation, global trade, and often, environmental concern.
NP-9 plays a role many have never heard of, but its impact ripples through everyday essentials ranging from medical creams to laboratory reagents. The molecule is built from a nonylphenol backbone, capped with nine ethylene oxide units to give a structure that thrives at boundaries between water and oils. This surfactant quality shows up in formulations designed for cleanliness or better absorption, but what sticks out is the tight regulation expected from BP, EP, and USP standards. Suppliers document every batch, tracking both purity and performance, keeping up the kind of records needed to satisfy international regulators. No batch heads out the door without running a gauntlet of checks for moisture, pH, trace metals, and byproducts, because small slipups carry consequences downstream in sensitive medical settings.
Here’s where NP-9 wins over formulators: As a waxy to liquid substance at room temperature, it pours easily and resists freezing under normal storage. It blends into water to form clear solutions, signaling to chemists that molecules are flexing their hydrophilic chains on command. Molecular weight runs high—upwards of 600 g/mol—thanks to nine repeating units of ethylene oxide, yet the nonyl group hangs on to some hydrophobic punch. NP-9 rides the line between oil and water, creating micelles and carrying substances from one side of the chemical fence to the other. This amphiphilic nature shows up not just in pharma work, but anywhere fine dispersion gets results, including textiles and agrochemicals.
Spec sheets for NP-9 in pharmaceutical quality don’t end with chemical formulae. Labels spell out expected purity, usually over 98%, and scan for impurities below specific ppm thresholds. Heavy metals earn special attention, with lead, mercury, arsenic, and cadmium listed by assay. Water content, sometimes overlooked with less regulated ingredients, demands tight control to prevent unwanted side reactions. Clear guidelines define color and clarity, and storage instructions call for sealed containers out of direct light, not just for stability but to protect against environmental seepage. Packaging leaves no room for ambiguity: drum weights, batch numbers, expiration dates, and hazard information follow global SDS templates, meeting the BP, EP, and USP requirements side by side.
Creating NP-9 means bringing together nonylphenol and ethylene oxide under conditions that neither home kitchens nor general factories can match. Scale-up relies on carefully metered addition of ethylene oxide to nonylphenol in the presence of a basic catalyst—often potassium hydroxide—inside reactors built to contain both heat and pressure. Exothermic reactions need constant vigilance, since runaway heat can spell disaster. At the end, water washes help strip away unreacted ingredients and salts, followed by vacuum distillation to chase off volatiles. Factories that supply the pharma market have to document every step, minimizing potential for cross-contamination and following cGMP recommendations. Plant workers recall that even slight shifts in reactant ratios or catalyst efficiency can change product performance, a reminder that chemistry often pushes up against the limits of engineering.
NP-9’s chemical behavior centers around the polyoxyethylene chain’s affinity for hydrogen bonding—and the phenolic head’s reactivity. Under acidic or basic conditions, the ether chain length can be shaved or extended, tailoring solubility for different drugs. NP-9 can be sulfonated for anionic surfactant properties or reacted with fatty acids to produce derivatives with better spreadability in ointments. In the pharmaceutical arena, these modifications extend shelf life or reduce irritation, allowing companies to tweak molecule behavior for the job at hand. The challenge sits in balancing chemical ambition with toxicity concerns—a single tweak means retesting each variable, especially under European REACH regulatory scrutiny.
NP-9 travels with aliases: Nonoxynol-9, Polyoxyethylene (9) nonylphenol ether, and sometimes Polidocanol or Igepal CO-630. Brand names stick depending on region, and generics attend different purity standards. Labels and MSDS sheets keep these straight to avoid confusion, as even closely related surfactants can carry distinct safety and performance profiles. Pharmacies and suppliers bend over backward clarifying whether their NP-9 matches the grade called for by USP or EP, since only pharmaceutical-grade NP-9 avoids some of the impurities common in industrial counterparts. The network of synonyms both empowers global trade and complicates regulation, something that sends quality assurance teams back to the documents, triple-checking sources.
Pharmaceutical uses demand the tightest safety standards. Plant safety officers train all new hires in handling ethylene oxide, which is as unpredictable as it is necessary, and treat every transfer as a hazard. Finished NP-9 is less volatile, but storage calls for sealed drums, with ventilation systems in place against slow leaks. Spill contingencies grab a permanent spot on the wall, and personal protective equipment stays standard. Upstream, suppliers carry out rigorous batch testing on every drum, with results uploaded to a chain-of-custody database. Downstream, final products meet residue analysis standards, with independent labs tracking parts-per-million limits.
NP-9 plays a supporting role in the pharma sector, especially in topical creams and drug delivery vehicles. Its surfactant edge allows oily active ingredients to disperse through otherwise water-heavy gels. RX creams, diagnostic reagents, and analytical assays lean on NP-9 both for performance and stability, making it a favorite among formulation chemists. Beyond pharma, factories turn to NP-9 for textile scouring, plastics processing, and paper making, though the bar for purity drops in those fields. Years working in formulation taught me that not all surfactants can handle the regulatory inspection NP-9 faces, and anyone trying to cross over from industrial to pharma grade gets a tough lesson in documentation and traceability.
Labs continue to study NP-9’s power to solubilize, enhance permeability, and cut through residues. Work on nanoemulsions and targeted drug delivery often references NP-9 as a control surfactant, benchmarking new materials against its reliable performance. Papers trace the fate of NP-9 derivatives in living tissue, tracking their behavior through imaging and chromatography. The push for greener chemistry now also drives research teams to maintain NP-9’s benefits but with lower environmental and biological footprint. That shift challenges not just the formulation but how supply chains operate, with more labs turning to biodegradable analogues or shorter-chain homologs.
Debate over NP-9’s safety refuses to die down. Decades ago, NP-9 hit headlines when aquatic toxicology studies showed hormone-like effects in exposed wildlife. Environmental persistence haunted suppliers, and the chemical’s slow breakdown led to tighter scrutiny by agencies like the EPA and ECHA. Human toxicity sits lower on the scale, but every application prompts a risk assessment—and, in pharma use, a battery of skin, eye, and inhalation tests. Chronic exposure studies track metabolism and excretion, while acute tests flag tightly defined exposure thresholds. Regulatory panels regularly review new studies, splitting hairs over what level of exposure deserves warning labels or restrictions. Lessons learned drive product reformulation, but they also underscore the need for tighter waste treatment and better spill response systems around every processing site.
Attention now turns to alternatives, both for environmental comfort and to anticipate tighter regulations. Chemists draw inspiration from NP-9’s structure but swap in linear alcohols or sugar-based heads for faster biodegradation. Pharma companies invest in greener synthesis routes, leveraging enzymes or biocatalysts to cut down on feedstock waste and residual toxicity. Regulators keep signaling to the industry that more changes are coming, making it essential for anyone depending on NP-9 to hedge by investing in robust supply chains and R&D efforts aimed at next-generation surfactants. The delicate balance between proven performance and environmental stewardship keeps NP-9 near the top of the discussion list, reminding all players that innovation rarely stands still in the world of surfactants and pharmaceuticals.
Nonylphenol Polyoxyethylene Ether 9, or Np-9, isn’t something most people think about, but it plays a role you can’t miss in pharmaceutical work. I’ve seen chemists rely on this compound for its knack at breaking down barriers between oil and water. Np-9 works as a nonionic surfactant—sort of like how dish soap lets grease come off pots. In pharmaceutical labs, it does heavy lifting by helping oils and waters mix in ways that let drug makers build tablets, creams, and even oral liquids.
As someone who’s watched and worked in drug manufacturing, this surfactant matters most in processes where the ingredients just don’t want to get along. Picture a cough syrup that separates before use—you wouldn’t trust it. Np-9 steps in to keep everything blended, letting active ingredients do their job from the first dose to the last drop in the bottle. It goes beyond just making things look good. Stable emulsions prevent issues that could affect how a drug acts in the body.
Beyond drug formulations, Np-9 makes itself useful in cleaning. Pharmaceutical production lines demand careful cleanup so nothing lingers between batches. Np-9 breaks down stubborn residues. Machines and tanks need this thorough cleaning to prevent unwanted chemical reactions or contamination.
Safety requirements in drug manufacturing run strict. The British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) set quality marks that Np-9 meets when made for pharma use. Purity standards make sure it doesn’t bring in contaminants that could risk patient health.
Use of Np-9 doesn’t come without baggage. I’ve read about its environmental persistence—meaning once this stuff gets into water or soil, it doesn’t leave easily. Reports from agencies, including the EPA and ECHA, note nonylphenol-based surfactants break down slowly and can impact aquatic life even at low doses. Some regions have set limits or pushed for safer alternatives because of these concerns.
On the health side, the amounts left in finished medicines remain tightly controlled, but production workers need good ventilation and protective gear to avoid unnecessary exposure. Good manufacturing practice (GMP) dictates checks all along the supply chain—from raw chemical drum to packaged pills.
Many companies look for biodegradable surfactants and greener substitutes, trying to cut down the environmental toll. A colleague once described the process of switching to newer, plant-based surfactants as tricky—you still want your drugs to work the same way, and stability can change with new components. Still, progress can be steady. Investment in research, plus regulatory support, helps make those alternatives more available and better tested.
Some suppliers run take-back programs or guide their clients on safe disposal. Steps like these lower the odds of toxic runoff or accidental spills. Companies who pay attention to both safety and sustainability earn more trust from regulators and patients. From the ground up, careful choices in the pharma supply chain shape how safe and effective the final medicine is.
Np-9 isn’t a household name, but in pharma circles, it gets attention because it tackles stubborn problems. As the industry keeps balancing patient needs, quality control, and responsibility to the environment, every ingredient faces questions. I’ve seen innovation move fast in recent years—safer, greener surfactants keep getting better, and that’s good for everyone who relies on a safe supply of medicine.
Pharmaceutical production relies on a short list of materials that help move the process along safely and efficiently. Np-9 Pharma Grade steps up as one of these, serving as a nonionic surfactant, crucial in both drug research and manufacturing. It holds a reputation for reliability, which people in the field depend on to tackle daily challenges in formulation and purification.
Np-9 Pharma Grade has a well-defined makeup. Chemically, it’s known as Nonylphenol Ethoxylate with about nine ethylene oxide units per molecule. The HLB (Hydrophilic-Lipophilic Balance) value slopes toward the upper teens, which makes this grade great at working in water-based systems. The molecular weight tends to fall between 600 and 630 g/mol, and it pours clear or nearly so, showing no visible particles and almost always appearing as a clear to pale yellow liquid.
Purity matters in every batch, not just for regulatory hurdles, but for patient safety. Certified Np-9 Pharma Grade commonly runs above 99% assay. Heavy metals remain well below 10 ppm, and no detectable free phenol gets through the manufacturing process, so it doesn’t disrupt sensitive components or bring risk to the final medicine.
Experience in drug development drives home how easily a minor impurity or swing in surfactant grade triggers headaches and wasted resources. When working on protein purification or prepping active pharmaceutical ingredients (APIs), even a hint of contamination blocks progress. Some manufacturers take purity for granted, but the value only becomes obvious with a failed batch or an out-of-spec analysis.
Np-9 Pharma Grade’s consistent purity supports reproducible results, limiting the trial-and-error cycle that ties up time and raises costs. In solid dose development, its performance as a wetting agent helps actives dissolve and distribute smoothly, addressing the most common source of variability: inconsistent mixing. Quality control leans heavily on this sort of reliability, since poor surfactant behavior can turn up as cloudy solutions or product rejections late in process validation.
Despite its benefits, Np-9 belongs to the nonylphenol group, which brings environmental scrutiny. Ecotoxicity and bioaccumulation risks prompted some countries to clamp down on its broader use. Regulatory filings for drug products require tight documentation and traceability for every excipient, and surfactants draw extra attention.
One way forward sits in the push for greener chemistry. Companies already search for alternative surfactants with less impact outside the lab without losing the performance that keeps products on spec. Strict sourcing standards, third-party testing, and transparent supply chains all reduce surprises during audits and FDA reviews.
Day-to-day, the trick comes down to using just as much Np-9 as process development proves necessary and pulling data from every run to spot trends before they cause regulatory snags. On the operational side, close collaboration with suppliers keeps everyone honest about test results, changes in specification, and long-term sustainability planning.
Every production line weights up risk, cost, and patient safety. Np-9 Pharma Grade sits in the thick of this work in many pharmaceutical applications, valued for its chemical clarity and steady performance. As watchdogs and the public raise the bar for transparency and environmental impact, the industry can’t afford to ignore either the trusted track record or the growing need for responsible use and alternatives.
I’ve seen NP-9 on plenty of ingredient lists, especially in labs that handle chemical processing and manufacturing. Nonylphenol ethoxylate, or NP-9, shows up in processes where strong detergency or emulsification matters. Companies lean on it for cleaning, extraction, and sometimes even as a surfactant. Yet, as useful as NP-9 proves for industry, its use in pharmaceuticals raises some tough questions. British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) create the yardsticks for drug safety, and not everything makes the cut.
BP, EP, and USP lay down strict requirements for anything that touches a tablet or a vial. Each expects heavy data—identity, purity, limits on contaminant levels, precise manufacturing records, and toxicology. These books don’t just want a substance to work in the lab; they ask for evidence that it won’t harm humans, directly or through traces left in finished drugs. NP-9 isn’t featured as an approved pharmaceutical excipient in any of these references. Pharmaceutical companies using any component must show regulators that nothing in the finished product crosses known safety limits for toxins, carcinogens, hormonal disruptors, or unproven additives.
Years back, I watched colleagues search for documentation supporting NP-9 as pharma-grade. They hit roadblocks. The main concern relates to safety. NP-9 is known to break down into nonylphenol. This breakdown product troubles toxicologists—it doesn’t degrade well in the environment and disrupts hormone systems in animals and, possibly, humans. Several governments have limited or banned NP-9 in specific applications. The European Union, for example, lists nonylphenol on the REACH candidate list for substances of very high concern because of these effects. That reputation shadows NP-9’s status in medicinal products.
The pharmacopoeias focus not just on whether an ingredient does its job but whether it leaves trace residues that could risk long-term health. Regulators expect companies to use excipients and processing aids that either feature directly in BP, EP, or USP, or at least have robust safety reports and precedents in the literature. NP-9 doesn’t cut it on this front. No current monograph supports NP-9 use in pharmaceutical excipients or handling.
Plenty of ingredients gain official listing because their safety data holds up under regulatory and scientific scrutiny. Polysorbates, for example, turn up often, along with polyethylene glycols, both well documented and widely trusted. Using these aligns with the expectations set by regulators and major pharmacopeias. I’ve watched drug formulations switch from NP-9 to these safer, recognized alternatives without performance loss—just fewer headaches on compliance audits.
Pharma companies look to sources like the BP, EP, and USP for more than just legal cover. They want scientific assurance that their drugs reach patients without unexpected health or regulatory risks. The case of NP-9 shows the importance of ongoing, transparent safety work around any chemical likely to enter the pharmaceutical supply chain. For now, using NP-9 in drug production falls short of the mark. Regulators, scientists, and ethical manufacturers all push for safer, proven chemical tools in the lab and the plant. That’s not just about following rules—it’s about building trust every time a patient takes a pill.
Storing chemicals like Nonylphenol Polyoxyethylene Ether 9 (often called NP-9) calls for more than just any space on the shelf. This is a surfactant that sees a lot of use in textile processing, cleaning products, and industrial applications. Despite its versatility, NP-9 can break down and form hazardous byproducts if kept under poor conditions. From my time in both small workshops and larger industrial settings, overlooking storage with these chemicals always ends up costing far more than expected—in dollars, in time, and sometimes in health.
Temperature swings do a lot of damage to surfactants like NP-9. High heat over time can lead to yellowing or even decomposition, releasing harmful compounds. Cold causes the liquid to thicken or solidify, making it tough to use and tough to measure. The best bet has always been finding a cool, dry, and well-ventilated spot. Most manufacturers flag a range around 5°C to 35°C as safe. If storage happens near steam pipes or in uninsulated basements, things can go wrong fast—I've seen containers swell, caps crack, and product quality slide. And let’s be honest, replacing whole drums due to improper storage eats away at the bottom line with nothing to show for it.
Storing NP-9 near strong acids, alkalis, or oxidizers is bad news. Even spills or drips from shelves above risk setting off unwanted chemical reactions. I remember a site supervisor who learned this lesson hard after storing cleaning acids right above surfactant containers—one leak, and the cleanup was a costly nightmare. Separate storage spaces for incompatible substances do more than check off regulatory boxes. They guard the health of everyone in the facility, and that’s not something you gamble on.
Steel drums work, but plastic containers usually hold up best against any long-term effects of the chemical itself. It’s crucial to keep lids tightly shut and containers upright because NP-9 will pick up moisture if left open. Moisture leads to clumping or a change in viscosity, sometimes rendering the product useless. From my own experience, taking an extra minute to re-cap drums and double-check labels saves headaches. Unlabeled or poorly sealed containers always end up causing confusion or waste. This extra care protects both the end-user and others down the chain.
Frequent inspections sometimes feel like overkill, but they catch problems before they grow. Aside from visual checks for leaks and deformation, feeling the container’s outside temperature can give early warning of overheating. Training staff to recognize early signs of product change—color, odor, or consistency—turns everyone into an extra layer of protection. Records help, too. Keeping a log of storage temperature and any observed changes means small issues get solved before they turn into big ones.
Dealing with NP-9 safely isn’t complicated, but it requires discipline. Location, container choice, separation from reactives, and regular checks add up to fewer accidents and fewer product quality problems. Most importantly, these habits protect colleagues and end users from real harm. Experience shows that once these habits are regular practice, workplaces save money, time, and reputation—while keeping everyone safer along the way.
The world of chemicals used in pharma gets murky fast. Np-9, or nonylphenol ethoxylate-9, has turned up in lots of industrial cleaners and detergents. Some labs have considered it in pharmaceutical settings as a surfactant or emulsifier. It gets solutions to mix and drugs to dissolve, something drug makers constantly juggle.
No one wants a toxic chemical floating around in what they swallow or inject. In my chemistry experience, clear answers matter, especially with patient safety. Reports tell a grim story for Np-9. Its structure breaks down into nonylphenol, which science has flagged as an endocrine disruptor. It tweaks hormone balance in animals and likely does similar things in humans. Endocrine disruptors have earned lots of attention in recent years—some folks even link them to issues like early puberty, lower fertility, or cancer risk. Nobody’s comfortable chalking these risks up as theoretical anymore.
European regulators cracked down long ago. They don’t allow nonylphenol ethoxylates in products tied to food, drugs, or cosmetics. Studies keep finding broken down bits of Np-9 in rivers and groundwater around the globe. Water treatment plants don’t seem able to catch most of it. Aquatic creatures feel the hit—their systems scramble to deal with the chemical, and population drops follow. For people, this becomes a twofold risk: through drug contamination or through water and environment.
Hard to ignore the human side in the lab. Technicians breathing in fine mists or handling spills face skin and eye irritation at the least. Chronic contact? Risks grow. I remember the strict gloves-and-goggles routines whenever my team handled ethoxylates; nobody took chances after seeing what unprotected contact could do. As drug facilities have ramped up their safety standards, Np-9 looks riskier compared to safer and more studied surfactants. You just can’t justify much exposure for workers or patients when cleaner options exist.
As more data rolls in, drug companies don’t want the headache of recalls or reputation damage. Polyethylene glycols, polysorbates, and other modern surfactants check more safety boxes and come supported by more thorough studies. They don’t carry the same breakdown risks or hormone story. The shift is already visible: clean-room managers and R&D teams opt for these ingredients, knowing the scrutiny only tightens over time.
In the US, the FDA classifies Np-9 as an unapproved ingredient in pharmaceutical products. Any trace in final medicines raises red flags in audits. In my experience, companies prefer to show they’ve anticipated these questions ahead of time rather than scramble for proof later.
The best move? Push for industry-wide bans and transparency from chemical suppliers. Let the burden shift to those who introduce risky chemicals, not on regulators to catch every violation. Ongoing work with green chemistry can open up surfactants that break down more easily and don’t linger in people or wildlife. In labs, regular training and updated protocols help too. No chemical is harmless just because it improves solubility—the bigger-picture cost shows up downstream, in health and in the ecosystem.
| Names | |
| Preferred IUPAC name | 2-(2-(2-(2-(2-(2-(2-(2-(2-nonylphenoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethanol |
| Other names |
Nonylphenol Ethoxylate 9 EO NP-9 NPE-9 Polyoxyethylene Nonylphenyl Ether 9 Nonylphenol Polyethoxylate 9 Nonylphenol Ethoxylate, 9-mole Nonoxynol-9 Nonylphenoxy Poly(ethyleneoxy) Ethanol 9 |
| Pronunciation | /nɒˈnɪl.fiˌnɒl ˌpɒl.iˌɒk.siˈɒθ.iˌliːn ˈiː.θər/ |
| Identifiers | |
| CAS Number | 9016-45-9 |
| Beilstein Reference | 1742024 |
| ChEBI | CHEBI:34359 |
| ChEMBL | CHEMBL4280808 |
| ChemSpider | 19793736 |
| DrugBank | DB14163 |
| ECHA InfoCard | ECHA InfoCard: 02-2119552461-55-XXXX |
| EC Number | EC 500-024-6 |
| Gmelin Reference | 67343 |
| KEGG | C19609 |
| MeSH | D009638 |
| PubChem CID | 22833556 |
| RTECS number | RN1998E00MG |
| UNII | C5AU1KGQ8I |
| UN number | UN3082 |
| CompTox Dashboard (EPA) | C449600 |
| Properties | |
| Chemical formula | C24H42O10 |
| Molar mass | 616.85 g/mol |
| Appearance | Clear to light yellow liquid. |
| Odor | Odorless |
| Density | 1.06 g/cm3 |
| Solubility in water | Soluble in water |
| log P | 4.48 |
| Vapor pressure | Negligible |
| Acidity (pKa) | 7.0 – 8.0 |
| Basicity (pKb) | 4.6 |
| Refractive index (nD) | 1.455 |
| Viscosity | Viscosity: 180-220 mPa.s |
| Dipole moment | 4.2 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 680 J/(mol·K) |
| Std enthalpy of combustion (ΔcH⦵298) | -5154 kJ/mol |
| Pharmacology | |
| ATC code | D06AX |
| Hazards | |
| GHS labelling | GHS07, GHS09, Warning, H315, H319, H411 |
| Pictograms | ☠️⚠️🌊🐟 |
| Signal word | Warning |
| Hazard statements | H302, H315, H318, H411 |
| Precautionary statements | P261, P273, P280, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | > 250 °C |
| Autoignition temperature | 230°C |
| Lethal dose or concentration | LD₅₀ (oral, rat): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): 1310 mg/kg (oral, rat) |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Nonylphenol Polyoxyethylene Ether 9 (NP-9) is not specifically established by OSHA or ACGIH. |
| REL (Recommended) | 0.1 – 1 mg/m³ |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Alkylphenol ethoxylates Nonylphenol ethoxylate Octylphenol ethoxylate Nonylphenol Polyethylene glycol Polyoxyethylene nonylphenyl ether Triton X-100 Nonidet P-40 Polysorbate 20 |
Chengguan District, Lanzhou, Gansu, China
